Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO
Authors:
Top Cited Papers
Open Access
- 18 June 2024
- journal article
- research article
- Published by Elsevier in Current Research in Toxicology
- Vol. 7, 100182
Abstract
No abstract availableKeywords
Funding Information
- University of Alberta
This publication has 81 references indexed in Scilit:
- Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 studyAnnals of Clinical and Translational Neurology, 2020
- Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 SkippingJAMA Neurology, 2020
- Approving a Problematic Muscular Dystrophy DrugJAMA, 2016
- Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophyAnnals of Neurology, 2015
- The Dystrophin Complex: Structure, Function, and Implications for Therapy2015
- The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy MutationsHuman Mutation, 2015
- Eteplirsen for the treatment of Duchenne muscular dystrophyAnnals of Neurology, 2013
- VBP15, a novel anti‐inflammatory and membrane‐stabilizer, improves muscular dystrophy without side effectsEMBO Molecular Medicine, 2013
- Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebaseHuman Mutation, 2009
- Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame ruleMuscle & Nerve, 2006